Scientific Reference
KLOW Protocol (GHK-Cu + TB-500 + BPC-157 + KPV)
The KLOW Protocol is a four-peptide regenerative blend combining GHK-Cu, TB-500 (Thymosin Beta-4), BPC-157, and KPV. It builds upon the GLOW protocol by incorporating KPV, a tripeptide with anti-inflammatory activity, to enhance tolerability and broaden mechanistic coverage. Typical formulations contain approximately 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual peptides have established research backgrounds, no clinical trials have evaluated this specific combination, and all effects remain theoretical based on additive and complementary mechanisms.
Mechanism of Action
The KLOW Protocol integrates four complementary mechanisms: GHK-Cu modulates gene expression and stimulates collagen synthesis; TB-500 enhances cell migration and cytoskeletal repair; BPC-157 upregulates growth factors and promotes angiogenesis; and KPV inhibits NF-κB signaling, reducing inflammation. Together, these pathways aim to create a synergistic regenerative and anti-inflammatory environment, though this combination has not been clinically validated.
Molecular Information
- Type: Multi-peptide regenerative protocol